A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

NCT03122522 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Melanoma

Interventions

DRUG: ipilimumab
DRUG: nivolumab

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]